Generic drugs in dermatology: part II

Journal of the American Academy of Dermatology
Michael Payette, Jane M Grant-Kels

Abstract

In part I, we discussed new drug development, reviewed the history of the generic drug industry, described how generic drugs are approved by the US Food and Drug Administration, and defined the concepts of bioequivalence and therapeutic equivalence. Herein, we explore various factors impacting generic drug use across the different parties involved: the prescriber, the pharmacist, the patient, and the payer. We also include original cost analysis of dermatologic brand name and generic drugs and show the potential cost savings that can be achieved through generic substitution. We conclude with a review of the data addressing potential differences in the effectiveness of brand name versus generic drugs in dermatology. The cost of brand name and generic medications is highly variable by pharmacy, state, and payer. We used one source (www.drugstore.com) as an example and for consistency across all medications discussed herein. Prices included here may not reflect actual retail prices across the United States.

References

Jan 1, 1989·Annual Review of Pharmacology and Toxicology·R B Stoughton
May 1, 1989·Journal of the American Academy of Dermatology·D B JacksonJ D Guin
Sep 1, 1995·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·R Taniguchi
Feb 9, 1985·Journal of Health Economics·F M Scherer
Jun 15, 2000·Journal of the American Pharmaceutical Association : APhA·J M Ganther, D H Kreling
Oct 12, 2000·Archives of Internal Medicine·S ReichertE A Halm
Aug 7, 2001·Journal of the American Pharmaceutical Association : APhA·F J AscioneL S Welage
Dec 25, 2003·Clinical Therapeutics·Peter Meredith
Jan 17, 2004·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Robert I GarisMichael C Makoid
Feb 18, 2004·Journal of the American Pharmacists Association : JAPhA·Robert I Garis, Bartholomew E Clark
Aug 27, 2004·The New England Journal of Medicine·F M Scherer
Sep 28, 2007·PLoS Medicine·G Michael AllanNatasha Wiebe
Mar 6, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Mark V SiracuseRobert I Garis
Dec 4, 2008·JAMA : the Journal of the American Medical Association·Aaron S KesselheimWilliam H Shrank
Jan 9, 2009·International Journal of Health Care Finance and Economics·John A Rizzo, Richard Zeckhauser
May 21, 2009·Dermatologic Therapy·John R PetersCecelia M Parise
Oct 13, 2009·Personality & Social Psychology Bulletin·Heejung S Kim, Aimee Drolet
Aug 24, 2010·Journal of Managed Care Pharmacy : JMCP·Joshua N Liberman, M Christopher Roebuck

❮ Previous
Next ❯

Citations

Jan 10, 2018·The International Journal of Health Planning and Management·Tomoya TachiHitomi Teramachi
May 23, 2013·Current Opinion in Pediatrics·James G H Dinulos

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.